Seegene
Seegene makes multiplex PCR test kits and instruments for infectious disease diagnosis.
On the record
Checkpoint: H1 2026 earnings release, showing whether non-respiratory panel growth stays above 30%
The call
Seegene is rebuilding revenue on GI, HPV, and STI panels after the COVID crash, while the same big diagnostics makers it always competed against keep selling rival panels in its markets.
Seegene designs and sells machines and test kits that quickly diagnose infectious diseases like COVID, flu, and sexually transmitted infections. The company is profitable and its products work well, but Cepheid, Roche, Abbott, and Hologic are much larger competitors selling similar tests, and these rivals have the money and scale to match or beat Seegene's technology. The business recovered nicely after COVID crashed it in 2020, but the real question is whether Seegene can keep growing its non-COVID test business faster than its giant competitors can copy or improve upon what it makes.
Why
01
AI pressure: None apparent. AI models don't run PCR chemistry or handle lab samples, so no AI product currently displaces this testing step. Could AI do the core job? Unlikely.
02
Bigger players: Cepheid (Danaher), Roche, Abbott, bioMerieux. These bigger diagnostics makers already sell competing multiplex syndromic panels in the same hospitals and labs today. Could a giant copy it? Yes, easily.
03
What protects it. FDA/CE clearances, patented DPO/TOCE/MuDT chemistry, and an installed base of instruments locked into Seegene's kits.
What would change this call
Seegene's non-respiratory (GI/HPV/STI) panel growth in Q2/H1 2026 earnings falls below 30% for two straight quarters. Would show the growth story is stalling before it offsets respiratory test decline.
Roche, Cepheid, or Abbott launches a high-multiplex syndromic panel priced near Seegene's level within the next year. Would show a major incumbent directly targeting Seegene's core price/performance niche.
Seegene's stock price and analyst commentary around the August 2026 Global Million Clinical Study data release. Would show whether real-world data translates into visible adoption or investor confidence gains.
Roche, Cepheid, or Abbott launches a high-multiplex syndromic panel priced near Seegene's level within the next year. Would show a major incumbent directly targeting Seegene's core price/performance niche.
Seegene's stock price and analyst commentary around the August 2026 Global Million Clinical Study data release. Would show whether real-world data translates into visible adoption or investor confidence gains.
Key numbers
- FY2025 revenue 474.23B KRW, up 14.5% YoY
- Q1 2026 revenue 129.1B KRW, up 11.3% YoY
- Q1 2026 operating profit up 58.6% YoY to 23.6B KRW
Named risks
- Revenue remains far below 2020 COVID peak of $957M despite recent double-digit growth.
- Direct competition from larger incumbents (Roche, Abbott, Danaher/Cepheid, bioMerieux, Hologic) with greater scale.
- Global headcount declined about 18% from 2023 to end 2025, signaling contraction pressure.
- Shareholder activism over depressed share price could resurface, pressuring management decisions.
- Integration execution risk from Dandi Mecca acquisition and Werfen joint venture ongoing through 2026.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Cepheid (Danaher) | contesting | GeneXpert point-of-care platform competes directly in decentralized molecular testing as of 2026 |
| bioMerieux (BioFire) | contesting | BioFire syndromic multi-pathogen panels rival Seegene's respiratory and GI panels directly |
| Roche Diagnostics | contesting | Cobas platform competes in HPV and broad molecular testing menus, per 2023 assay comparison study |
| Abbott Molecular | contesting | RealTime platform overlaps with Seegene assays in comparative studies published August 2023 |
| Hologic | contesting | Aptima/Panther platform competes directly in STI and women's health molecular testing |
Questions people ask
- Is Seegene in financial trouble?
- Seegene suffered a severe crash after the pandemic, with FY2023 revenue falling to ₩367.4 billion and an operating loss of ₩486.2 billion, but it has since returned to profitability. FY2025 operating profit came in between ₩34.5 and 60.0 billion on revenue of ₩474.2 billion (about $355M), and Q1 2026 operating profit grew 59% year over year, suggesting the immediate crisis has eased even though the company remains a smaller player.
- Who are Seegene's biggest competitors?
- Seegene's main competitors are Danaher's BioFire FilmArray, which dominates US syndromic PCR testing with a large installed base, along with Roche Diagnostics and Abbott Laboratories, which hold most of the remaining molecular diagnostics share. QIAGEN also competes directly in the same multiplex syndromic-PCR segment. Together these rivals hold an estimated 60% of the molecular diagnostics market, leaving Seegene as a smaller challenger as of the July 2026 assessment.
- Is Seegene at risk from AI?
- AI does not appear to be a direct threat to Seegene right now; the assessment lists its AI threat status as not-applicable because no AI product currently displaces PCR test kits. AI-driven test interpretation and lab automation are emerging in diagnostics, but as of the July 2026 assessment this is not one of Seegene's identified pressure points.
- Could a larger company just copy what Seegene does?
- Direct copying is only partially possible. Seegene holds patented multiplex PCR chemistry and regulatory approvals across many countries, which the July 2026 assessment flags as a shield. However, this protection rests mainly on its expanded test menu covering COVID-era panels and broader syndromic infection testing rather than any pricing or distribution advantage over larger rivals like Roche, Abbott, and Danaher's BioFire, so the moat is moderate rather than strong.
- What should I watch to see if Seegene is turning around?
- Two dated checkpoints matter: Seegene's H1/Q2 2026 earnings report, due by August 31, 2026, will show whether it posts a third consecutive profitable quarter after Q1 2026's 59% year-over-year operating profit growth. By December 31, 2026, it is also worth checking whether its CURECA and STAgora pilot programs have converted into signed hospital contracts with reported revenue.
Timeline
- 2026-07-08Launched Global Million Clinical Study to collect real-world data from 1 million test cases starting August 2026
- 2026-05-08Reported Q1 2026 operating profit up 58.6% YoY to 23.6B KRW on non-respiratory panel growth
- 2026-04-26Debuted CURECA automated PCR system and STAgora platform at ESCMID Global 2026
- 2025-12-01Opened new French subsidiary to expand European market presence
- 2025-05-01Formed joint venture with Werfen for diagnostic equipment development
- 2025-02-01Agreed to acquire Dandi Mecca automated-equipment developer, finalized by September 2025
- 2024-01-01Launched SGDDS AI-assisted assay development platform in partnership with Springer Nature
- 2023-07-10Minority shareholders rallied demanding CEO Chun's resignation over sluggish share price
- 2010-09-01IPO on KOSDAQ raising $16.6M
- 2000-01-01Founded in Seoul by Dr. Jong-Yoon Chun
Revision history
30 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Seegene
- gurufocus.com (2026-07-30)
- Seegene, Inc. 내부자 거래 및 지분 구조
- Seegene (KOSDAQ) (2026-06-28)
- Seegene's Q1 operating profit jumps 59% on non-respiratory test growth (2026-05-08)
- Seegene 2026 Company Profile
- Seegene Number of Employees 2026 (2026-06-29)
- Seegene debuts STAgora platform, automated PCR system at ESCMID Global 2026 (2026-04-26)
- Perspective: Achieving a World Free From All Diseases (2025-07-24)
- Seegene launches Global Million Clinical Study (2026-07-08)
- Seegene Inc Company Profile (2025-05-20)
- Angered by sluggish share prices, Seegene retail shareholders hold rally (2023-07-10)